Last CNY13.27 CNY
Change Today +0.04 / 0.30%
Volume 3.0M
002693 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

hainan shuangcheng pharmac-a (002693) Snapshot

Open
CNY13.23
Previous Close
CNY13.23
Day High
CNY13.36
Day Low
CNY13.08
52 Week High
08/14/14 - CNY14.25
52 Week Low
09/2/13 - CNY7.66
Market Cap
3.6B
Average Volume 10 Days
9.4M
EPS TTM
CNY0.25
Shares Outstanding
270.0M
EX-Date
05/22/14
P/E TM
53.8x
Dividend
CNY0.13
Dividend Yield
1.00%
Current Stock Chart for HAINAN SHUANGCHENG PHARMAC-A (002693)

Related News

No related news articles were found.

hainan shuangcheng pharmac-a (002693) Related Businessweek News

No Related Businessweek News Found

hainan shuangcheng pharmac-a (002693) Details

Hainan Shuangcheng Pharmaceutical Co., Ltd. is engaged in the research, development, manufacture, marketing, and sale of chemically synthesized peptide drugs and active pharmaceutical ingredients. It provides Thymalfasin for injection, which is used in the treatment of chronic hepatitis B, as well as used as a vaccine for patients with immune system functions suppressed; and Levocarnitine for injection to treat carnitine deficiency induced complications. The company also offers Clindamycin Hydrochloride for injection for amygdalitis, suppurative otitis media, and nasosinusitis; acute bronchitis, acute episode of chronic bronchitis, pneumonia, lung abscess, and bronchiectasia concurrent infection; skin and soft tissue infections; urinary system infection, acute urethritis, acute pyelonephritis, and prostatitis; and osteomyelitis, septicemia, peritonitis, and oral infection. In addition, it provides Thymopentin for injection to treat chronic hepatitis B; various primary or secondary T cell immunodeficiency diseases, such as children innate immunodeficiency disease; autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, etc.; various diseases with impaired cell immunity functions; and supplementary treatment of rumor diseases. Further, the company offers Famotidine for injection for patients with peptic ulcer hemorrhage; and intercurrent acute gastric mucosal lesion under stress condition, and gastrointestinal bleeding that is caused by nonsteroidal anti-inflammatory drugs. Additionally, it provides Somatostatin for injection for treating acute haemorrhage from oesophageal varices; acute haemorrhage from gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis; pancreas, gallbladder, and intestinal fistula; prophylaxis; and diabetic ketoacidosis, as well as for treating postoperative complications following pancreatic surgery. The company was founded in 2000 and is based in Haikou, the People’s Republic of China.

Founded in 2000

hainan shuangcheng pharmac-a (002693) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hainan shuangcheng pharmac-a (002693) Key Developments

Hainan Shuangcheng Pharmaceutical Co., Ltd. to Report First Half, 2014 Results on Aug 15, 2014

Hainan Shuangcheng Pharmaceutical Co., Ltd. announced that they will report first half, 2014 results on Aug 15, 2014

Hainan Shuangcheng Pharmaceutical Co., Ltd. Approves Dividend for the Year 2013

Hainan Shuangcheng Pharmaceutical Co., Ltd. announced that the shareholders at its Annual General Meeting held on May 8, 2014 approved a cash dividend (tax included) of CNY 2.00000000 per 10 shares for the full year of 2013.

Hainan Shuangcheng Pharmaceutical Co., Ltd. to Report Q1, 2014 Results on Apr 25, 2014

Hainan Shuangcheng Pharmaceutical Co., Ltd. announced that they will report Q1, 2014 results on Apr 25, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002693:CH CNY13.27 CNY +0.04

002693 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002693.
View Industry Companies
 

Industry Analysis

002693

Industry Average

Valuation 002693 Industry Range
Price/Earnings 57.2x
Price/Sales 20.2x
Price/Book 4.7x
Price/Cash Flow 57.4x
TEV/Sales 21.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAINAN SHUANGCHENG PHARMAC-A, please visit www.shuangchengmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.